Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2024; 16(9): 4006-4013
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.4006
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.4006
Human bone marrow mesenchymal stem cell-derived exosomes loaded with gemcitabine inhibit pancreatic cancer cell proliferation by enhancing apoptosis
Zu-Gui Tang, Tie-Mei Chen, Zhe Wang, Xi-Cheng Wang, Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, Guangdong Province, China
Zu-Gui Tang, Yi Kong, Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen 518000, Guangdong Province, China
Yi Lu, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong Province, China
Co-corresponding authors: Xi-Cheng Wang and Yi Kong.
Author contributions: Wang XC and Kong Y designed the study and were responsible for the work, and they are the co-corresponding authors of this manuscript. Tang ZG, Chen TM, and Lu Y performed the research; Wang Z analyzed the data; Kong Y wrote the manuscript. All authors have read and approved the final manuscript.
Supported by Guangdong Basic and Applied Basic Research Foundation , No. 2019A1515011609 ; the Project of Educational Commission of Guangdong Province of China , No. 2018KQNCX124 ; and Guangzhou Science and Technology Key Point Project , No. 202103000041 .
Institutional review board statement: Our study exclusively involves in vitro cell experiments and does not involve human subjects or animals. Therefore, it does not require ethical approval.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi Kong, PhD, Associate Professor, Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, No. 1068 Xueyuan Avenue, Nanshan District, Shenzhen 518000, Guangdong Province, China. yi.kong@siat.ac.cn
Received: May 25, 2024
Revised: June 29, 2024
Accepted: July 26, 2024
Published online: September 15, 2024
Processing time: 106 Days and 21.8 Hours
Revised: June 29, 2024
Accepted: July 26, 2024
Published online: September 15, 2024
Processing time: 106 Days and 21.8 Hours
Core Tip
Core Tip: This study investigates the utilization of exosomes derived from human bone marrow mesenchymal stem cells as a novel system to deliver gemcitabine (GEM) for the treatment of pancreatic cancer. Through the optimization of GEM loading into exosomes, the results indicate that exosomes loaded with GEM (Exo-GEM) have a potent cytotoxicity against pancreatic cancer cells by enhancing their apoptosis in vitro. These findings underscore the potential of Exo-GEM as a more efficient and targeted therapeutic approach for enhancing therapeutic efficacy in patients with pancreatic cancer.